Literature DB >> 11506816

Mechanism of up-regulated gap junctional intercellular communication during chemoprevention and chemotherapy of cancer.

J E Trosko1, C C Chang.   

Abstract

To develop a strategy for efficacious intervention in order to prevent or treat various cancers, one must understand the basic mechanism(s) by which various anticancer dietary factors prevent or reverse the tumor promotion or progression phases. Carcinogenesis is a multistage, multimechanism process, involving the irreversible alteration of a stem cell (the "initiation" phase), followed by the clonal proliferation of the initiated stem cell (the "promotion" phase), from which the acquisition of the invasive and metastatic phenotypes are generated (the "progression" phase). While intervention to prevent or treat cancer could occur at each step, the objective of this presentation will focus on the rate limiting step, the promotion phase.Gap junctional intercellular communication (GJIC) has been hypothesized to regulate growth control, differentiation and apoptosis. Most normal, contact-inhibited cells have functional GJIC, while most, if not all, tumor cells have dysfunctional homologous or heterologous GJIC. Cancer cells are characterized by the lack of growth control, by the inability to terminally differentiate and by resistance to apoptosis. Chemical tumor promoters (phorbol esters, DDT, phenobarbital, unsaturated fatty acids, saccharin, etc.) inhibit GJIC in a reversible fashion and at doses above particular chemical thresholds. Various oncogenes (e.g. ras, raf, neu, src, mos) down-regulate GJIC while several tumor suppressor genes can up-regulate GJIC. Antitumor promoters (retinoids, carotenoids, green tea components) and antioncogene drugs (i.e. lovastatin) can up-regulate GJIC. Transfection of gap junction genes ("connexins") into GJIC-deficient tumor cells can restore GJIC, growth control and reduce tumorigenicity. On the other hand, antisense gap junction genes can convert the phenotype of a non-tumorigenic cell to that of a tumorigenic one. Recently, a specific connexin knockout mouse was shown to have a higher frequency of spontaneous and induced liver cancers. Evidence from these studies clearly suggests that dietary factors can modulate GJIC by inducing various signal transducing systems. The modulation can either down-regulate GJIC and lead to tumor promotion or it can up-regulate GJIC and lead to suppression of the initiated cells. Multiple mechanisms of up- or down-regulation of GJIC exist, as well as multiple types of pre-malignant and malignant tumor cells that are unable able to have functional GJIC. GJIC can be down-regulated by mutations and by epigenetic means. Alteration of gene expression at the transcriptional, translational or post-translational levels would require specific dietary prevention or treatment of cancer. In conclusion, if dietary prevention or treatment of cancer is to occur, it must ameliorate the growth-stimulatory effects, above threshold levels, of chemicals, growth factors or hormones, that trigger various mitogenic/antiapoptotic signal transducing systems that block GJIC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11506816     DOI: 10.1016/s0027-5107(01)00181-6

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  25 in total

Review 1.  Developmental regulation of gap junctions and their role in mammary epithelial cell differentiation.

Authors:  Marwan E El-Sabban; Lina F Abi-Mosleh; Rabih S Talhouk
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-10       Impact factor: 2.673

2.  Nutritional factors and progenitor cell differentiation.

Authors:  A Dembinska-Kie C; A Polus; J Grzybowska; B Kiec-Wilk; A Balwierz; J Keijer; G Schmitz
Journal:  Genes Nutr       Date:  2007-10       Impact factor: 5.523

3.  Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.

Authors:  Ying Ding; Thu Annelise Nguyen
Journal:  J Cancer Sci Ther       Date:  2012-11-01

4.  Anti-breast cancer agents, quinolines, targeting gap junction.

Authors:  Julie Bernzweig; Brian Heiniger; Keshar Prasain; Jianyu Lu; Duy H Hua; Thu A Nguyen
Journal:  Med Chem       Date:  2011-09       Impact factor: 2.745

5.  Influence of gap junction intercellular communication composed of connexin 43 on the antineoplastic effect of adriamycin in breast cancer cells.

Authors:  Guojun Jiang; Shuying Dong; Meiling Yu; Xi Han; Chao Zheng; Xiaoguang Zhu; Xuhui Tong
Journal:  Oncol Lett       Date:  2016-12-07       Impact factor: 2.967

6.  Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea.

Authors:  Taichang Jang; Todd Savarese; Hoi Pang Low; Sunchin Kim; Hannes Vogel; David Lapointe; Timothy Duong; N Scott Litofsky; James M Weimann; Alonzo H Ross; Lawrence Recht
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

7.  Connexins and apoptotic transformation.

Authors:  Audrone Kalvelyte; Ausra Imbrasaite; Angele Bukauskiene; Vytas K Verselis; Feliksas F Bukauskas
Journal:  Biochem Pharmacol       Date:  2003-10-15       Impact factor: 5.858

8.  Inhibition of gap junctional Intercellular communication in WB-F344 rat liver epithelial cells by triphenyltin chloride through MAPK and PI3-kinase pathways.

Authors:  Chung-Hsun Lee; I-Hui Chen; Chia-Rong Lee; Chih-Hsien Chi; Ming-Che Tsai; Jin-Lian Tsai; Hsiu-Fen Lin
Journal:  J Occup Med Toxicol       Date:  2010-06-30       Impact factor: 2.646

9.  Both early and late stages of hepatocarcinogenesis are enhanced in Cx32 dominant negative mutant transgenic rats with disrupted gap junctional intercellular communication.

Authors:  Naomi Hokaiwado; Makoto Asamoto; Mitsuru Futakuchi; Kumiko Ogawa; Satoru Takahashi; Tomoyuki Shirai
Journal:  J Membr Biol       Date:  2007-11-03       Impact factor: 1.843

10.  Chemopreventive Agents Attenuate Rapid Inhibition of Gap Junctional Intercellular Communication Induced by Environmental Toxicants.

Authors:  Pavel Babica; Lucie Čtveráčková; Zuzana Lenčešová; James E Trosko; Brad L Upham
Journal:  Nutr Cancer       Date:  2016-06-07       Impact factor: 2.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.